Literature DB >> 22302930

Aliskiren-induced chyloperitoneum in a patient on peritoneal dialysis.

Y Saka, H Tachi, H Sakurai, M Tawada, A Sawai, Y Shimamura, M Mizuno, S Maruyama, S Matsuo, Y Ito.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22302930      PMCID： PMC3525370          DOI： 10.3747/pdi.2011.00049

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN： 0896-8608            Impact factor:   1.756


× No keyword cloud information.
  10 in total

1.  Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in rats.

Authors:  Chun-Yen Ke; Chia-Chi Lee; Chung-Jen Lee; Yi-Maun Subeq; Ru-Ping Lee; Bang-Gee Hsu
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

2.  Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.

Authors:  M Katoh; M Nakajima; N Shimada; H Yamazaki; T Yokoi
Journal:  Eur J Clin Pharmacol       Date:  2000 Feb-Mar       Impact factor: 2.953

3.  Incidence and clinical course of lercanidipine-associated cloudy effluent in continuous ambulatory peritoneal dialysis.

Authors:  P-J Hsiao; H-W Lin; C-C Sung; C-W Wang; P Chu; S-H Lin
Journal:  Clin Nephrol       Date:  2010-09       Impact factor: 0.975

4.  The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.

Authors:  Hiromichi Suzuki; Tsutomu Inoue; Kazuhiro Kobayashi; Junko Shoda; Hidetomo Nakamoto
Journal:  Adv Perit Dial       Date:  2006

5.  Diltiazem suppresses collagen synthesis and IL-1beta-induced TGF-beta1 production on human peritoneal mesothelial cells.

Authors:  Cheng-Chung Fang; Chung-Jen Yen; Yung-Ming Chen; Tzong-Shinn Chu; Ming-Tsan Lin; Ju-Yeh Yang; Tun-Jun Tsai
Journal:  Nephrol Dial Transplant       Date:  2006-01-18       Impact factor: 5.992

6.  Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis.

Authors:  K Yoshimoto; S Saima; Y Nakamura; M Nakayama; H Kubo; Y Kawaguchi; H Nishitani; Y Nakamura; A Yasui; K Yokoyama; S Kuriyama; D Shirai; A Kugiyama; K Hayano; H Fukui; I Horigome; Y Amagasaki; Y Tsubakihara; T Kamekawa; R Ando; S Tomura; R Okamoto; S Miwa; T Koyama; H Echizen
Journal:  Clin Nephrol       Date:  1998-08       Impact factor: 0.975

7.  Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.

Authors:  S Vaidyanathan; J Valencia; C Kemp; C Zhao; C-M Yeh; M-N Bizot; J Denouel; H A Dieterich; W P Dole
Journal:  Int J Clin Pract       Date:  2006-11       Impact factor: 2.503

8.  Lercanidipine-induced chyloperitoneum in patients on peritoneal dialysis.

Authors:  Wei-Shun Yang; Jenq-Wen Huang; Huei-Wen Chen; Tun-Jun Tsai; Kwan-Dun Wu
Journal:  Perit Dial Int       Date:  2008 Nov-Dec       Impact factor: 1.756

9.  A drug-induced turbid peritoneal dialysate in five patients treated with continuous ambulatory peritoneal dialysis.

Authors:  K Yoshimoto; S Saima; H Echizen; Y Nakamura; T Ishizaki
Journal:  Clin Nephrol       Date:  1993-08       Impact factor: 0.975

Review 10.  Chylous ascites: an unusual complication of peritoneal dialysis. A case report and literature review.

Authors:  Chee Kay Cheung; Arif Khwaja
Journal:  Perit Dial Int       Date:  2008 May-Jun       Impact factor: 1.756
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.